Analgesics
Antiandrogens
Azvudine
Bromhexine
Budesonide
Colchicine
Conv. Plasma
Curcumin
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Ivermectin
Lifestyle
Melatonin
Metformin
Minerals
Molnupiravir
Monoclonals
Naso/orophar..
Nigella Sativa
Nitazoxanide
Paxlovid
Quercetin
Remdesivir
Thermotherapy
Vitamins
More

Other
Feedback
Home
Top
 
Feedback
Home
c19early.org COVID-19 treatment researchVitamin AVitamin A (more..)
Melatonin Meta
Metformin Meta
Azvudine Meta
Bromhexine Meta Molnupiravir Meta
Budesonide Meta
Colchicine Meta
Conv. Plasma Meta Nigella Sativa Meta
Curcumin Meta Nitazoxanide Meta
Famotidine Meta Paxlovid Meta
Favipiravir Meta Quercetin Meta
Fluvoxamine Meta Remdesivir Meta
Hydroxychlor.. Meta Thermotherapy Meta
Ivermectin Meta

Summary of COVID-19 vitamin A studies

Studies   Meta Analysis   Hide extended summaries

24 patient vitamin A long COVID RCT: 75% lower PASC (p=0.05).
RCT 24 patients with olfactory dysfunction post-COVID-19 in Hong Kong, showing significantly improved recovery with the addition of vitamin A to aerosolised diffuser olfactory training. 25,000IU vitamin A for 14 days.

Jun 2023, Brain Sciences, https://www.mdpi.com/2076-3425/13/7/1014, https://c19p.org/chung

60 patient vitamin A ICU RCT: 89% lower mortality (p=0.11), 41% lower hospitalization (p=0.25), and 45% improved recovery (p=0.001).
Small RCT 60 ICU patients in Iran, 30 treated with vitamins A, B, C, D, and E, showing significant improvement in SOFA score and several inflammatory markers at day 7 with treatment. 5,000 IU vitamin A daily, 600,000 IU vitamin D once, 300 IU of vitamin E twice a day, 500 mg vitamin C four times a day, and one ampule daily of B vitamins [thiamine nitrate 3.1 mg, sodium riboflavin phosphate 4.9 mg (corresponding to vitamin B2 3.6 mg), nicotinamide 40 mg, pyridoxine hydrochloride 4.9 mg (corresponding to vitamin B6 4.0 mg), sodium pantothenate 16.5 mg (corresponding to pantothenic acid 15 mg), sodium ascorbate 113 mg (corresponding to vitamin C 100 mg), biotin 60 μg, folic acid 400 μg, and cyanocobalamin 5 μg].

Nov 2021, Trials, https://link.springer.com/article/10.1186/s13063-021-05795-4/fulltext.html, https://c19p.org/beigmohammadi2a

vitamin A prophylaxis study: 35% lower severe cases (p=0.28), 24% lower hospitalization (p=0.29), and 31% fewer cases (p=0.006).
Mendelian randomization study suggesting a causal association between retinol and related proteins (RBP4, RDH16, CRABP1) and COVID-19. The study found that genetically-predicted higher retinol levels were associated with lower COVID-19 susceptibility. There was a lower risk of hospitalization and severity without statistical significance. Authors conclude that the results support a potential protective effect of vitamin A treatment for COVID-19. Given the lack of clear evidence for pleiotropy, and the lower precision of the MR-Egger estimates, the IVW estimates are likely more reliable in this case when the IVW and MR-Egger estimates differ.

Apr 2024, BMC Pulmonary Medicine, https://bmcpulmmed.biomedcentral.com/articles/10.1186/s12890-024-03013-w, https://c19p.org/wang31

180 patient vitamin A early treatment RCT: 26% lower hospitalization (p=0.63) and 32% improved recovery (p=0.53).
RCT 91 vitamin A and 91 control patients in Iran, showing improved recovery with treatment. All patients received HCQ. 25,000IU/day oral vitamin A for 10 days.

Aug 2022, Eastern Mediterranean Health J., http://www.emro.who.int/in-press/research/evaluation-and-comparison-of-the-effect-of-vitamin-a-supplementation-with-standard-therapies-in-the-treatment-of-patients-with-covid-19.html, https://c19p.org/rohani

60 patient vitamin A late treatment RCT: 38% improved recovery (p=0.53).
RCT 90 outpatients with post-COVID-19 anosmia showing significant improvements in smell alterations with olfactory training after 3 and 12 months. Adding oral vitamin A to olfactory training resulted in higher rates of improvement, but the difference was not statistically significant.

Jun 2024, Brazilian J. Otorhinolaryngology, https://www.sciencedirect.com/science/article/pii/S1808869424000661, https://c19p.org/taheri2

3,955 patient vitamin A prophylaxis study: 17% lower hospitalization (p=0.04) and 11% fewer symptomatic cases (p=0.03).
Analysis of nutrient intake and COVID-19 outcomes for 3,996 people in Iran, showing lower risk of COVID-19 hospitalization with sufficient vitamin A, vitamin C, and selenium intake, with statistical significance for vitamin A and selenium.

May 2023, The Clinical Respiratory J., https://onlinelibrary.wiley.com/doi/10.1111/crj.13632, https://c19p.org/vaisi

2,148 patient vitamin A prophylaxis study: 21% lower hospitalization (p=0.4) and 21% lower severe cases (p=0.36).
Retrospective 2,148 COVID-19 recovered patients in Jordan, showing no significant differences in the risk of severity and hospitalization with vitamin A prophylaxis.

Feb 2022, Bosnian J. Basic Medical Sciences, https://www.bjbms.org/ojs/index.php/bjbms/article/view/7009, https://c19p.org/nimera

15,227 patient vitamin A prophylaxis study: 56% fewer cases (p=0.41).
Prospective survey-based study with 15,227 people in the UK, showing lower risk of COVID-19 cases with vitamin A, vitamin D, zinc, selenium, probiotics, and inhaled corticosteroids; and higher risk with metformin and vitamin C. Statistical significance was not reached for any of these. Except for vitamin D, the results for treatments we follow were only adjusted for age, sex, duration of participation, and test frequency. NCT04330599. COVIDENCE UK.

Mar 2021, Thorax, https://thorax.bmj.com/content/early/2021/11/02/thoraxjnl-2021-217487, https://c19p.org/holta

144 patient vitamin A late treatment study: 26% lower mortality (p=1).
Prospective study of 144 hospitalized COVID-19 patients in the DRC and South Sudan, showing no significant difference with vitamin A treatment in unadjusted results with only 8 patients receiving vitamin A.

Oct 2022, PLOS Global Public Health, https://journals.plos.org/plosone/article?id=10.1371/journal.pgph.0000924, https://c19p.org/doocyva

140 patient vitamin A early treatment study: 86% lower mortality (p=0.002).
Retrospective 70 severe condition patients treated with vitamin A (200,000IU for two days), salbutamol, and budesonide, and 70 patients not treated with vitamin A, showing significantly lower mortality with the addition of vitamin A.

Dec 2020, EurAsian J. Biosciences-7350, http://ejobios.org/article/therapeutic-effect-of-vitamin-a-on-severe-covid-19-patients-8517, https://c19p.org/alsumiadai2

100 patient vitamin A early treatment study: 67% lower progression (p=0.27) and 38% faster recovery.
Treatment and prophylaxis studies of vitamin A in Iraq. The treatment study contained 100 patients, 50 treated with 200,000IU vitamin A for two days, showing lower progression to severe disease, and shorter duration of symptoms. The prophylaxis study contained 209 contacts of COVID-19 patients, 97 treated with vitamin A, showing significantly lower cases with treatment, and shorter duration of symptoms.

Jan 2021, Systematic Reviews in Pharmacy, https://www.researchgate.net/publication/351637178_THERAPEUTIC_EFFECT_OF_VITAMIN_A_ON_COVID-19_PATIENTS_AND_ITS_PROPHYLACTIC_EFFECT_ON_CONTACTS, https://c19p.org/alsumiadai

27 patient vitamin A late treatment study: 282% higher mortality (p=0.001).
Retrospective 27 severe COVID-19 patients and 23 non-COVID-19 patients, showing significantly lower vitamin A levels in COVID-19 patients (0.37mg/L vs. 0.52 mg/L, p<0.001). 10 of 27 COVID-19 patients received vitamin A, with higher mortality. Group details are not provided but authors note that 8 of 10 had comorbidities.

Jan 2021, medRxiv, https://www.medrxiv.org/content/10.1101/2021.01.30.21250844v1, https://c19p.org/sarohan

30 patient vitamin A late treatment RCT: 76% slower improvement (p=0.21) and 8% longer hospitalization (p=0.49).
RCT 30 hospitalized patients in Iran, showing no significant difference with vitamin A treatment. All patients received HCQ. 50,000 IU/day intramuscular vitamin A for up to 2 weeks.

Oct 2022, Nutrition and Health, http://journals.sagepub.com/doi/10.1177/02601060221129144, https://c19p.org/somi
Please send us corrections, updates, or comments. c19early involves the extraction of 100,000+ datapoints from thousands of papers. Community updates help ensure high accuracy. Treatments and other interventions are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Thanks for your feedback! Please search before submitting papers and note that studies are listed under the date they were first available, which may be the date of an earlier preprint.
Submit